Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT05446961Phase 2Completed
Phase 2, randomised, double-blind trial (4 arms), sponsored by SENAI CIMATEC. Primary endpoints: Number new SARS-CoV-2 cases at 21 days assessed by RT-PCR and Number of participants with severe COVID pneumonia at 21 days. Started Mar 2021; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT05446961.